218 related articles for article (PubMed ID: 21412829)
1. Homeostatic changes of the endocannabinoid system in Parkinson's disease.
Pisani V; Madeo G; Tassone A; Sciamanna G; Maccarrone M; Stanzione P; Pisani A
Mov Disord; 2011 Feb; 26(2):216-22. PubMed ID: 21412829
[TBL] [Abstract][Full Text] [Related]
2. Expression of the endocannabinoid system in fibroblasts and myofascial tissues.
McPartland JM
J Bodyw Mov Ther; 2008 Apr; 12(2):169-82. PubMed ID: 19083670
[TBL] [Abstract][Full Text] [Related]
3. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs.
Gaetani S; Dipasquale P; Romano A; Righetti L; Cassano T; Piomelli D; Cuomo V
Int Rev Neurobiol; 2009; 85():57-72. PubMed ID: 19607961
[TBL] [Abstract][Full Text] [Related]
4. The endocannabinoid system in gp120-mediated insults and HIV-associated dementia.
Bari M; Rapino C; Mozetic P; Maccarrone M
Exp Neurol; 2010 Jul; 224(1):74-84. PubMed ID: 20353779
[TBL] [Abstract][Full Text] [Related]
5. From endocannabinoid profiling to 'endocannabinoid therapeutics'.
Ligresti A; Petrosino S; Di Marzo V
Curr Opin Chem Biol; 2009 Jun; 13(3):321-31. PubMed ID: 19497779
[TBL] [Abstract][Full Text] [Related]
6. Experimental autoimmune encephalomyelitis disrupts endocannabinoid-mediated neuroprotection.
Witting A; Chen L; Cudaback E; Straiker A; Walter L; Rickman B; Möller T; Brosnan C; Stella N
Proc Natl Acad Sci U S A; 2006 Apr; 103(16):6362-7. PubMed ID: 16571660
[TBL] [Abstract][Full Text] [Related]
7. The polarised life of the endocannabinoid system in CNS development.
Anavi-Goffer S; Mulder J
Chembiochem; 2009 Jul; 10(10):1591-8. PubMed ID: 19533710
[TBL] [Abstract][Full Text] [Related]
8. Role of lipids and lipid signaling in the development of cannabinoid tolerance.
Martin BR
Life Sci; 2005 Aug; 77(14):1543-58. PubMed ID: 15949820
[TBL] [Abstract][Full Text] [Related]
9. Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease.
Silverdale MA; McGuire S; McInnes A; Crossman AR; Brotchie JM
Exp Neurol; 2001 Jun; 169(2):400-6. PubMed ID: 11358453
[TBL] [Abstract][Full Text] [Related]
10. The endocannabinoid system in Parkinson's disease.
Di Filippo M; Picconi B; Tozzi A; Ghiglieri V; Rossi A; Calabresi P
Curr Pharm Des; 2008; 14(23):2337-47. PubMed ID: 18781984
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of endocannabinoid-hydrolysing enzyme inhibitors.
Saario SM; Laitinen JT
Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):287-93. PubMed ID: 17910610
[TBL] [Abstract][Full Text] [Related]
12. DAGL-dependent endocannabinoid signalling: roles in axonal pathfinding, synaptic plasticity and adult neurogenesis.
Oudin MJ; Hobbs C; Doherty P
Eur J Neurosci; 2011 Nov; 34(10):1634-46. PubMed ID: 22103420
[TBL] [Abstract][Full Text] [Related]
13. The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases.
Maccarrone M; Battista N; Centonze D
Prog Neurobiol; 2007 Apr; 81(5-6):349-79. PubMed ID: 17276576
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the endocannabinoid system: neuroprotection or neurotoxicity?
Fowler CJ; Rojo ML; Rodriguez-Gaztelumendi A
Exp Neurol; 2010 Jul; 224(1):37-47. PubMed ID: 20353772
[TBL] [Abstract][Full Text] [Related]
15. The endocannabinoid system in neuropathological states.
Orgado JM; Fernández-Ruiz J; Romero J
Int Rev Psychiatry; 2009 Apr; 21(2):172-80. PubMed ID: 19367511
[TBL] [Abstract][Full Text] [Related]
16. Symptom-related changes of endocannabinoid and palmitoylethanolamide levels in brain areas of R6/2 mice, a transgenic model of Huntington's disease.
Bisogno T; Martire A; Petrosino S; Popoli P; Di Marzo V
Neurochem Int; 2008 Jan; 52(1-2):307-13. PubMed ID: 17664017
[TBL] [Abstract][Full Text] [Related]
17. The endocannabinoid system and the neuroendocrine control of hydromineral balance.
Ruginsk SG; Vechiato FM; Elias LL; Antunes-Rodrigues J
J Neuroendocrinol; 2014 Jun; 26(6):370-6. PubMed ID: 24750469
[TBL] [Abstract][Full Text] [Related]
18. Interplay between endocannabinoids, steroids and cytokines in the control of human reproduction.
Battista N; Pasquariello N; Di Tommaso M; Maccarrone M
J Neuroendocrinol; 2008 May; 20 Suppl 1():82-9. PubMed ID: 18426505
[TBL] [Abstract][Full Text] [Related]
19. Dietary PUFAs and Exercise Dynamic Actions on Endocannabinoids in Brain: Consequences for Neural Plasticity and Neuroinflammation.
Park Y; Watkins BA
Adv Nutr; 2022 Oct; 13(5):1989-2001. PubMed ID: 35675221
[TBL] [Abstract][Full Text] [Related]
20. Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson's Disease: A Perspective on Associated Therapeutic Interventions.
Behl T; Kaur G; Bungau S; Jhanji R; Kumar A; Mehta V; Zengin G; Brata R; Hassan SSU; Fratila O
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
